TD Waterhouse Canada’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$108M Buy
502,971
+447,935
+814% +$99.4M 0.32% 61
2025
Q4
$12.6M Sell
55,036
-53,689
-49% -$12.2M 0.08% 177
2025
Q3
$26.6M Buy
108,725
+53,885
+98% +$11M 0.17% 110
2025
Q2
$10.4M Sell
54,840
-15,871
-22% -$2.95M 0.07% 185
2025
Q1
$14.6M Buy
70,711
+15,113
+27% +$2.94M 0.12% 150
2024
Q4
$9.88M Buy
55,598
+4,133
+8% +$760K 0.08% 188
2024
Q3
$10.1M Sell
51,465
-20,437
-28% -$3.81M 0.08% 181
2024
Q2
$12.3M Buy
71,902
+1,223
+2% +$203K 0.11% 159
2024
Q1
$13.3M Sell
70,679
-8,206
-10% -$1.41M 0.1% 163
2023
Q4
$13.3M Sell
78,885
-15,369
-16% -$2.24M 0.12% 135
2023
Q3
$14.4M Sell
94,254
-4,733
-5% -$695K 0.15% 113
2023
Q2
$13.9M Sell
98,987
-94,142
-49% -$13.8M 0.14% 116
2023
Q1
$31.8M Buy
193,129
+25,577
+15% +$3.91M 0.33% 59
2022
Q4
$27.9M Buy
167,552
+597
+0.4% +$91.5K 0.31% 60
2022
Q3
$23.6M Sell
166,955
-49,940
-23% -$7.17M 0.27% 67
2022
Q2
$34M Sell
216,895
-31,330
-13% -$4.79M 0.38% 49
2022
Q1
$39.7M Buy
248,225
+10,873
+5% +$1.58M 0.39% 54
2021
Q4
$31.7M Buy
+237,352
New +$28M 0.31% 66

Other funds holding ABBV

TD Waterhouse Canada's ABBV Position: Q1 2026 in Review

TD Waterhouse Canada increased its AbbVie (ABBV) stake by 814% in Q1 2026, buying an estimated $99.4M and bringing the position to 502,971 shares worth $108M. The position accounts for 0.32% of the portfolio, ranked #61.

TD Waterhouse Canada first reported a position in ABBV in Q4 2021 and has held it in 18 quarters since. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • TD Waterhouse Canada held 502,971 shares of AbbVie worth $108M as of Q1 2026.
  • TD Waterhouse Canada bought 447,935 AbbVie shares in Q1 2026, an estimated $99.4M.
  • AbbVie made up 0.32% of TD Waterhouse Canada's portfolio in Q1 2026, its #61 holding.
  • TD Waterhouse Canada first reported a position in AbbVie in Q4 2021 and has held it in 18 quarters since.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on TD Waterhouse Canada's 13F filing for Q1 2026, filed 12 May 2026.